A PRISMA-compliant meta-analysis of MDR1 polymorphisms and idiopathic nephrotic syndrome: Susceptibility and steroid responsiveness

Medicine (United States)

Volumn 96, Issue 24, 2017, Pages

  Han, Shi Sheng ^a   Xu, Yan Qiu ^a   Lu, Yan ^a   Gu, Xiang Chen ^a   Wang, Yi ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

MDR1; meta analysis; nephrotic syndrome; polymorphisms

Indexed keywords

MULTIDRUG RESISTANCE PROTEIN 1; STEROID; ABCB1 PROTEIN, HUMAN; MULTIDRUG RESISTANCE PROTEIN;

ARTICLE; CAUCASIAN; DRUG RESISTANCE; GENETIC SUSCEPTIBILITY; HAPLOTYPE; HUMAN; MOLECULAR PATHOLOGY; NEPHROTIC SYNDROME; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; STEROID THERAPY; SYSTEMATIC REVIEW; GENETIC PREDISPOSITION; GENETICS; META ANALYSIS;

DRUG RESISTANCE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; NEPHROTIC SYNDROME; P-GLYCOPROTEINS; POLYMORPHISM, SINGLE NUCLEOTIDE; STEROIDS;

EID: 85021859541     PISSN: 00257974     EISSN: 15365964     Source Type: Journal    
DOI: 10.1097/MD.0000000000007191     Document Type: Article

References (45)

1. Rheault MN. Nephrotic syndrome: updates and approaches to treatment. Curr Treat Options Peds 2016;2:94-103.
2. Lombel RM, Gipson DS, Hodson EM. Treatment of steroid-sensitive nephrotic syndrome: new guidelines from KDIGO. Pediatr Nephrol 2013;28:415-26.
3. Teeninga N, Kistvan Holthe JE, Van Rijswijk N, et al. Extending prednisolone treatment does not reduce relapses in childhood nephrotic syndrome. J Am Soc Nephrol 2013;24:149-59.
4. Beins NT, Dell KM. Long-term outcomes in children with steroidresistant nephrotic syndrome treated with calcineurin inhibitors. Front Pediatr 2015;27:104.
5. Cil O, Besbas N, Duzova A, et al. Genetic abnormalities and prognosis in patients with congenital and infantile nephrotic syndrome. Pediatr Nephrol 2015;30:1279-87.
6. Lovric S, Ashraf S, Tan W, et al. Genetic testing in steroid-resistant nephrotic syndrome: when and how. Nephrol Dial Transplant 2016;31:1802-13.
7. Becherucci F, Mazzinghi B, Provenzano A, et al. Lessons from genetics: is it time to revise the therapeutic approach to children with steroidresistant nephrotic syndrome? J Nephrol 2016;29:543-50.
8. Swierczewska M, Ostalska-Nowicka D, Kempisty B, et al. Molecular basis of mechanisms of steroid resistance in children with nephrotic syndrome. Acta Biochim Pol 2013;60:339-44.
9. Badr HS, El-Hawy MA, Helwa MA. P-glycoprotein activity in steroidresponsive vs. steroid-resistant nephrotic syndrome. Indian J Pediatr 2016;83:1222-6.
10. Wasilewska A, Zoch-Zwierz W, Pietruczuk M, et al. Expression of Pglycoprotein in lymphocytes from children with nephrotic syndrome, depending on their steroid response. Pediatr Nephrol 2006;21:1274-80.
11. Stachowski J, Zanker CB, Runowski D, et al. Resistance to therapy in primary nephrotic syndrome: effect of MDR1 gene activity [Polish]. Pol Merkur Lekarski 2000;8:218-21.
12. Youssef DM, Elbehidy RM, Abdelhalim HS, et al. Soluble interleukine-2 receptor and MDR1 gene expression levels as inflammatory biomarkers for prediction of steroid response in children with nephrotic syndrome. Iran J Kidney Dis 2011;5:154-61.
13. Hoffmeyer S, Burk O, von Richter O, et al. Functional polymorphisms of the human multidrug-resistance gene: multiple sequence variations and correlation of one allele with P-glycoprotein expression and activity in vivo. Proc Natl Acad Sci USA 2000;97:3473-8.
14. Youssef DM, Attia TA, El-Shal AS, et al. Multi-drug resistance-1 gene polymorphisms in nephrotic syndrome: impact on susceptibility and response to steroids. Gene 2013;530:201-7.
15. Cizmarikova M, Podracka L, Klimcakova L, et al. MDR1 polymorphisms and idiopathic nephrotic syndrome in Slovak children: preliminary results. Med Sci Monit 2015;21:59-68.
16. Jafar T, Prasad N, Agarwal V, et al. MDR-1 gene polymorphisms in steroid-responsive versus steroid-resistant nephrotic syndrome in children. Nephrol Dial Transplant 2011;26:3968-74.
17. Chiou YH, Wang LY, Wang TH, et al. Genetic polymorphisms influence the steroid treatment of children with idiopathic nephrotic syndrome. Pediatr Nephrol 2012;27:1511-7.
18. Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 2009;6:e1000097.
19. The primary nephrotic syndrome in children. Identification of patients with minimal change nephrotic syndrome from initial response to prednisone. A report of the International Study of Kidney Disease in Children. J Pediatr 1981;98:561-4.
20. Kodner C. Diagnosis and management of nephrotic syndrome in adults. Am Fam Physician 2016;93:479-85.
21. Hogan J, Radhakrishnan J. The treatment of minimal change disease in adults. J Am Soc Nephrol 2013;24:702-11.
22. Wells GA, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in metaanalyses. Available at: http://www.ohri.ca/programs/clinical-epidemiol ogy/oxford.htm. Accessed October 17, 2016.
23. Dou H,Ma E, Yin L, et al. The association between gene polymorphism of TCF7L2 and type 2 diabetes in Chinese Han population: a metaanalysis. PLoS One 2013;8:e59495.
24. Wang F, Ma YL, Zhang P, et al. A genetic variant in microRNA-196a2 is associated with increased cancer risk: a meta-analysis. Mol Biol Rep 2012;39:269-75.
25. Holm S. A simple sequentially rejective multiple test procedure. Scan J Stat 1979;6:65-70.
26. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 1995;57:289-300.
27. Zintzaras E, Ioannidis JP. Heterogeneity testing in meta-analysis of genome searches. Genet Epidemiol 2005;28:123-37.
28. DerSimonian R, Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986;7:177-88.
29. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. Biometrics 1994;50:1088-101.
30. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997;315:629-34.
31. Wasilewska A, Zalewski G, Chyczewski L, et al. MDR-1 gene polymorphisms and clinical course of steroid-responsive nephrotic syndrome in children. Pediatr Nephrol 2007;22:44-51.
32. Suvanto M, Jahnukainen T, Kestilä M, et al. Single nucleotide polymorphisms in pediatric idiopathic nephrotic syndrome. Int J Nephrol 2016;2016:1417456.
33. Safan MA, Elhelbawy NG, Midan DA, et al. ABCB1 polymorphisms and steroid treatment in children with idiopathic nephrotic syndrome. Br J Biomed Sci 2016;10:1-6.
34. Dhandapani MC, Venkatesan V, Rengaswamy NB, et al. Association of ACE and MDR1 gene polymorphisms with steroid resistance in children with idiopathic nephrotic syndrome. Genet Test Mol Biomarkers 2015;19:454-6.
35. Choi HJ, Cho HY, Ro H, et al. Polymorphisms of the MDR1 and MIF genes in children with nephrotic syndrome. Pediatr Nephrol 2011;26: 1981-8.
36. Fung KL, Pan J, Ohnuma S, et al. MDR1 synonymous polymorphisms alter transporter specificity and protein stability in a stable epithelial monolayer. Cancer Res 2014;74:598-608.
37. Marzolini C, Paus E, Buclin T, et al. Polymorphisms in human MDR1 (Pglycoprotein): recent advances and clinical relevance. Clin Pharmacol Ther 2004;75:13-33.
38. Brambila-Tapia AJ. MDR1 (ABCB1) polymorphisms: functional effects and clinical implications. Rev Invest Clin 2013;65:445-54.
39. Wolking S, Schaeffeler E, Lerche H, et al. Impact of genetic polymorphisms of ABCB1 (MDR1, P-Glycoprotein) on drug disposition and potential clinical implications: update of the literature. Clin Pharmacokinet 2015;54:709-35.
40. Wasilewska AM, Zoch-Zwierz WM, Pietruczuk M. Expression of Pglycoprotein in lymphocytes of children with nephrotic syndrome treated with glucocorticoids. Eur J Pediatr 2006;165:839-44.
41. Funaki S, Takahashi S,WadaN, et al.Multiple drug-resistant gene 1 in children with steroid-sensitive nephrotic syndrome. Pediatr Int 2008;50:159-61.
42. Kimchi-Sarfaty C, Oh JM, Kim IW, et al. A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 2007;315:525-8.
43. Komar AA. Silent SNPs: impact on gene function and phenotype. Pharmacogenomics 2007;8:1075-80.
44. Sauna ZE, Kimchi-Sarfaty C, Ambudkar SV, et al. Silent polymorphisms speak: how they affect pharmacogenomics and the treatment of cancer. Cancer Res 2007;60:9609-12.
45. Kim RB, Leake BF, Choo EF, et al. Identification of functionally variant MDR1 alleles among European Americans and African Americans. Clin Pharmacol Ther 2001;70:189-99.